Egypts Osteoporosis drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The International Osteoporosis Foundation reported that osteoporosis is a serious disease in the Middle East. It causes the bones to weaken, and they may break easily, become brittle or even develop cancer and infections.

Theprevalenceof osteoporosis is relatively high amongst theEgyptianpopulation and is associated with a wide range of risk factors and medical conditions. Reports show that 53.9% of postmenopausal women have osteopenia while 28.4% have osteoporosis. 21.9% of males aged 20-89 have osteoporosis. Among the primary concerns for the disease treatment market is low awareness among the population. Egyptian Guidelines for the Diagnosis and Management of Osteoporosis have been developed to optimize the use of the existing tools available for the early diagnosis of osteoporosis and to help general practitioners as well as specialists in screening persons with or without risk factors to avoid the occurrence of fractures, especially the first fracture.



Market Drivers

The prevalence of osteoporosis in Egypt has been rated at 28.4% in women and 21.9% in men, whereas 53.9% of women and 26% of men had osteopenia. In rural areas of Upper Egypt, the prevalence of osteoporosis in postmenopausal women was even higher reaching up to 47.8%.

Such high prevalence highlights the magnitude of the problem in terms of public health and adds to the scope of market growth for osteoporosis drugs in Egypt.

The two fastest-growing age groups in the country are the elderly (65+) and the near-elderly (60-64), whose numbers will increase by 2.8 and 2.3 times, respectively, by 2050, relative to what they are in 2020 and this is the age bracket most affected by Osteoporosis. High Sunlight keeps people inside and this again increases demand for treatment of bone-related disorders.

However, osteoporosis is not a national health priority in Egypt and even though guidelines have been developed, it is not endorsed by the government of the country. There is absolutely no reimbursement policy for therapy and treatments due to which people must pay. These factors bring resistance to the market growth for the disease.